Health-related quality of life in prostate cancer

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1094-1101

  Torvinen, Saku ^a,b   Färkkilä, Niilo ^a,b   Sintonen, Harri ^a   Saarto, Tiina ^c   Roine, Risto P ^d   Taari, Kimmo ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b GLAXOSMITHKLINE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CROSS-SECTIONAL STUDY; DIARRHEA; EXCRETION; FATIGUE; FINANCIAL DEFICIT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL BEHAVIOR; SLEEP; ASSESSMENT OF HUMANS; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; FINANCIAL MANAGEMENT; HEALTH RELATED QUALITY OF LIFE SCORE; HEALTH STATUS; METASTASIS; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

ANTINEOPLASTIC AGENT; GONADORELIN; ZOLEDRONIC ACID;

EID: 84880321509     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.760848     Document Type: Article

References (23)

1. Ferlay J, Parkin D M, Steliarova-Foucher E. E stimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
2. Schröd er FH. P rostate cancer around the world. A n overview. Urol Oncol 2010; 28: 663-7.
3. Finnish Cancer Registry [Internet]. Cancer Statistics. Available from: Http://www.cancerregistry.fi. 2012. [cited 2012 Sept 13].
4. Alibhai S M, Klotz L H. A systematic review of randomized trials in localized prostate cancer. Can J Urol 2004; 11: 2110-7.
5. Dahabreh IJ, Chung M, Balk EM, Y u WW, Mathew P, Lau J, et al. Active surveillance in men with localized prostate cancer: A systematic review. Ann Intern Med 2012; 156: 582-90.
6. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-8.
7. Albertsen P C, Aaronson N K, Muller M J, Keller SD, Ware JE, Jr. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207-16.
8. Sintonen H. O utcome measurement in acid-related diseases. PharmacoEconomics 1994; 5: 17-26.
9. Sintonen H. The 15D instrument of health-related quality of life: Properties and applications. Ann Med 2001; 33: 328-36.
10. Pickard A S, Neary MP, Cella D. E stimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007; 21: 70.
11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
12. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
13. Aromaa A, Koskinen S. H ealth and functional capacity in Finland. Baseline results of the Health 2000 health examination survey. Series B 12/2004. 2004:171 ed. 2004.
14. Statistical Package for the Social Sciences [computer program] . Version 20, 2012.
15. Saarni SI, Hä r kän en T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, et al. The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006; 15: 1403-14.
16. Brazier J, Roberts J, Tsuchiya A, Busschbach J, Tsuchiya A, Brazier J, et al. A comparison of the EQ-5D and SF-6D across seven patient groups-comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. Health Econ 2004; 13: 873-84.
17. Conner-Spady B, Suarez-Almazor ME. V ariation in the estimation of quality-adjusted life-years by different preferencebased instruments. Med Care 2003; 41: 791-801.
18. Lillegraven S, Kristiansen I S, Kvien TK. C omparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1762-7.
19. Marra CA, Esdaile JM, Guh D, Kopec JA, Brazier JE, Koehler BE, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004; 42: 1125-31.
20. Tsuchiya A, Brazier J, Roberts J. Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J Health Econ 2006; 25: 334-46.
21. Vainiola T, Pettilä V, Roine RP, Räsän en P, Rissanen A M, Sintonen H. Comparison of two utility instruments, the EQ-5D and the 15D, in the critical care setting. Intensive Care Med 2010; 36: 2090-3.
22. Jayadevappa R, Bloom BS, Chhatre S, Fomberstein KM, Wein AJ, Malkowicz SB. Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer. J Urol 2005; 174: 1059-64.
23. Song L, Northouse L L, Braun TM, Zhang L, Cimprich B, Ronis DL, et al. Assessing longitudinal quality of life in prostate cancer patients and their spouses: A multilevel modeling approach. Qual Life Res 2011; 20: 371-81.